Trinity named to Forbes World's Best Management Consulting Firms 2026 ranking for third consecutive year. Aug 20, 2026, 11:00 ET Recognition highlights Trinity's continued leadership in helping life sciences organizations navigate commercialization by integrating human expertise and artificial intelligence. WALTHAM, Mass., Aug. 20, 2026 /PRNewswire/ - Trinity, the leader in integrating human and artificial intelligence in life sciences commercialization, has been named to the Forbes World's Best Management Consulting Firms 2026 ranking for the third consecutive year. The annual ranking, developed by Forbes in partnership with Statista, recognizes the world's top consulting firms based on one of the industry's most comprehensive independent research efforts. This year's list reflects recommendations from more than 5,400 consulting partners and executives, feedback from approximately 3,700 senior client executives, and research spanning 31 countries across 13 industries and 15 consulting specialties. The recognition underscores Trinity's commitment to delivering innovative, data-driven solutions that help pharmaceutical, biotechnology and medical technology companies make smarter decisions across the product lifecycle. "Being recognized by Forbes for the third consecutive year is a tremendous honor and a reflection of the trust our clients place in us every day," said Scott Evangelista, Chief Executive Officer of Trinity. "The life sciences industry is evolving rapidly, driven by AI, data and increasing market complexity. We remain committed to helping our clients navigate that change with the strategic insight, scientific expertise and innovative technology they need to improve commercial performance and ultimately help patients." Over the past year, Trinity has continued to expand its AI-enabled commercialization capabilities, introducing new solutions that help life sciences organizations transform data into actionable intelligence. Building on its strategic brand transformation, the company has further strengthened its integrated portfolio of consulting, data, analytics and technology solutions designed to accelerate decision-making and improve commercial outcomes. The Forbes recognition adds to a growing list of honors for Trinity, reflecting the company's continued investment in innovation, client service and industry leadership. About Trinity Trinity powers the future of life sciences commercialization through the fusion of human and artificial intelligence. By blending deep therapeutic expertise and trusted human ingenuity with a purpose-built technology platform, Trinity accelerates clarity and confidence at every step of the commercialization journey - from pre-launch to scale to loss of exclusivity. For more than 30 years, the world's leading pharmaceutical, biotech, and medtech companies have relied on Trinity's foresight, execution, and partnership to deliver confident product launches, decisive market advantage, and measurable patient impact. During that time, Trinity expanded from its first office in Waltham, MA to 1,300 professionals across 14 offices and five continents, setting new industry standards in quality, responsiveness, and client partnership. For more information, visit Trinity at www.trinitylifesciences.com. SOURCE Trinity

Trinity has appointed Tina Durocher-Murphy as Chief People Officer as the company plans to double its business over the next few years. Based in Waltham, Massachusetts, Trinity focuses on helping clients commercialise life-saving drugs. Durocher-Murphy brings over two decades of human resources experience across life sciences and healthcare. She previously served as Chief People Officer at Precision Medicine Group and Millennium Physician Group, and held senior HR roles at PRA Health Sciences, Quintiles/IQVIA, and Abbott. In her new role, Durocher-Murphy will oversee talent acquisition, total rewards, learning and development, and culture programmes. She will lead Trinity's people strategy as the company blends human expertise with artificial intelligence for life sciences commercialisation. Trinity operates across 14 offices on five continents with 1,300 professionals.

Trinity's AI platform wins Pinnacle Award for innovation. Innovation in the life sciences game. Here comes a fascinating twist - Trinity snagged the Platinum Pinnacle Award for Best Use of AI Technology. Typically, when Investors Hangout, LLC talk about AI, Investors Hangout, LLC think about industries like finance or tech, but here it's a game-changer for life sciences. Trinity, the juggernaut in the commercialization solutions world, is getting recognized for its InsightsEDGE(TM) | Digital Twins platform. What makes this tick is its ability to mix AI with real-world data to offer smarter insights - something old-school market reports just can't do. Why this matters to patients and investors. The kicker with Trinity's platform is it's not just hot air. It's got real teeth in healthcare. Jonathan Jenkins from Trinity nailed it; this AI isn't some abstract concept. It's built on trusted data and real domain know-how, designed specifically for the life sciences. This isn't some hype pedestal here; it's transforming commercial teams beyond boring static reports. This is about dynamic, ever-evolving intelligence that saves time and costs less to boot - critical for any investor keeping tabs in this sector. The nuts and bolts of Digital Twins. Okay, let's peel back the layers. Trinity's prizewinner creates digital doubles - or 'twins' - of healthcare pros, patients, and payers. Think about it as an entire virtual ecosystem. Commercial teams are using these twins to simulate scenarios and test conversations, like a full-dress rehearsal for real-world strategies. This dynamic allows them to be ahead of the curve - anticipating shifts before they happen. It's like looking into the industry's crystal ball. Award impact and the bigger picture. Winning the pinnacle of Pinnacle Awards isn't just about the accolades; this spells a bigger message to the industry. This award reinforces Trinity's vision of merging AI with human insight, not as a replacement but as an enhancer. Scott Evangelista, the boss of the joint, highlighted that it aligns with their long-term strategy to innovate within the life sciences domain. Investors should note how this AI is positioned to change how decisions are made, potentially reshaping the commercialization journey itself. "Artificial intelligence delivers the greatest value when it is grounded in trusted data, deep domain expertise and rigorous scientific validation." - Jonathan Jenkins Trinity's expanding empire. Trinity's growth over the years hasn't been for nothing. From one office in Waltham, MA, to 1,300 folks across five continents - yeah, you'd call that expansion. They're not just big; they're setting the standards that others measure against. Both big pharma and up-and-coming biotechs rely on their vision and execution and, darn, it has paid off. The Pinnacle Award is just the cherry that puts other players on notice that Trinity is a force. Investor takeaway. For those with a keen eye on the life sciences space, Trinity's latest accolade provides more than just a shade of insight. This isn't just about Trinity snagging an award; it's about marking a shift in how disruptive innovations are grounded in the commercial realm. For investors, the key here is how Trinity turns AI into a decisive advantage, one that directly impacts commercialization strategies. Keep an eye on how these innovations continue to ripple through the industry - they might set the pace for future investments and technological adoption in life sciences.